Gadavyt

Description

Magcitgrape is a pharmaceutical compound characterized by its specific chemical composition and properties. The molecular weight of magcitgrape is not specified in the provided data. The chemical formula is also not detailed. The dosage form and appearance of magcitgrape are not included in the extracted information. Further details regarding inactive ingredients or additional characteristics are not available.

Uses and Indications

This drug is indicated for use in specific patient populations as determined by clinical guidelines. Currently, there are no specific indications or usage information provided. Additionally, there are no known teratogenic or nonteratogenic effects associated with this drug. Healthcare professionals are advised to consider the absence of detailed indications when prescribing this medication and to rely on clinical judgment and existing guidelines.

Dosage and Administration

For adults and children aged 12 years and older, the recommended dosage is between 1/2 to 1 bottle (10 fl. oz.). Each dose should be accompanied by a full 8 oz glass of liquid. These doses may be administered as a single daily dose or divided into multiple doses throughout the day.

For children aged 6 to under 12 years, the appropriate dosage is 1/3 to 1/2 bottle, also taken with a full 8 oz glass of liquid.

For children under 6 years of age, it is advised to consult a healthcare professional for appropriate dosing recommendations.

Contraindications

Use is contraindicated in patients experiencing rectal bleeding or those who do not have a bowel movement after use, as these may indicate a serious underlying condition. Additionally, the use of this product is contraindicated in individuals who require laxative treatment for more than one week, necessitating medical consultation.

Warnings and Precautions

Healthcare professionals should exercise caution when recommending this product. It is imperative to advise patients to consult a physician prior to use if they have any of the following conditions: kidney disease, a magnesium-restricted diet, a sodium-restricted diet, stomach pain, nausea, or vomiting. Additionally, patients who have experienced a sudden change in bowel habits lasting more than one week should also seek medical advice.

Patients currently taking prescription medications should be advised to consult with their doctor or pharmacist before using this product to avoid potential interactions.

While using this product, it is crucial that patients do not exceed the maximum recommended daily dosage within a 24-hour period to prevent adverse effects.

Patients should be instructed to discontinue use and contact their healthcare provider if they experience rectal bleeding or if there is no bowel movement following use, as these symptoms may indicate a serious underlying condition. Furthermore, if a laxative is required for more than one week, medical consultation is necessary.

In the event of an accidental overdose, immediate professional assistance should be sought, or the Poison Control Center (1-800-222-1222) should be contacted without delay.

Side Effects

Patients should be aware of several important warnings associated with the use of this product. It is advised that individuals consult a healthcare professional prior to use if they have a history of kidney disease, are on a magnesium-restricted or sodium-restricted diet, are experiencing stomach pain, nausea, or vomiting, or have noticed a sudden change in bowel habits lasting more than one week. Additionally, patients currently taking a prescription medication should seek guidance from a doctor or pharmacist before using this product.

While using this product, it is crucial for patients to adhere to the recommended dosage guidelines and not exceed the maximum daily dosage within a 24-hour period. Failure to follow these recommendations may lead to adverse reactions or complications.

Drug Interactions

Patients are advised to consult a healthcare professional, such as a doctor or pharmacist, prior to using this medication if they are currently taking any prescription drugs. This precaution is essential to identify potential drug interactions that may affect the efficacy or safety of the treatment.

It is important to monitor for any adverse effects or changes in therapeutic outcomes when combining this medication with other prescription therapies. Adjustments to dosage or additional monitoring may be necessary based on the specific interactions identified by the healthcare provider.

Packaging & NDC

Below are the non-prescription pack sizes of Gadavyt (magnesium citrate). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 6 to under 12 years may be administered 1/3 to 1/2 bottle mixed with a full 8 oz glass of liquid. For children under 6 years of age, it is advised to consult a doctor prior to use.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully weighed, as the effects on fetal outcomes and lactation are not fully established. It is essential for women of childbearing potential to seek medical advice to ensure the safety of both the mother and the developing fetus.

Lactation

Lactating mothers are advised to consult a healthcare professional prior to using this medication. There is currently no available data regarding the excretion of this drug in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment should consult a healthcare professional prior to use, particularly if they have a history of kidney disease. It is essential to assess renal function and consider potential dosing adjustments or monitoring requirements based on the degree of impairment.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

Overdosage of the medication can lead to serious health consequences. It is imperative that healthcare professionals adhere to the maximum recommended daily dosage to mitigate the risk of adverse effects.

Recommended Actions In the event of suspected overdosage, immediate medical attention should be sought. Healthcare providers are advised to monitor the patient closely for any signs of toxicity and to initiate appropriate management procedures based on the clinical presentation.

Potential Symptoms Symptoms of overdosage may vary depending on the specific medication involved but can include a range of physiological and psychological effects. It is crucial for healthcare professionals to be vigilant in recognizing these symptoms to ensure timely intervention.

Management Procedures Management of overdosage should be tailored to the individual patient and may involve supportive care, symptomatic treatment, and, if necessary, specific antidotes. Continuous assessment and monitoring of the patient's condition are essential to guide treatment decisions and ensure patient safety.

In summary, adherence to the recommended dosage guidelines is critical in preventing overdosage and its associated complications.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep this medication and all other drugs out of the reach of children to prevent accidental ingestion. It is crucial to emphasize the importance of safeguarding medications to ensure the safety of young children.

In the event of an accidental overdose, healthcare providers should instruct patients to seek professional assistance immediately. They should be informed to contact a Poison Control Center at 1-800-222-1222 for guidance on the necessary steps to take in such situations.

Storage and Handling

The product is supplied in configurations that include specific NDC numbers. It should be stored at room temperature, ensuring that it is protected from excessive heat and freezing conditions. Healthcare professionals are advised to discard any unused product within 24 hours of opening to maintain safety and efficacy.

Additional Clinical Information

The medication is administered orally, with specific dosing guidelines based on age. For adults and children aged 12 years and older, the recommended dose is between 1/2 to 1 bottle (10 fl. oz.), taken with a full 8 oz glass of liquid, either as a single daily dose or divided doses. For children aged 6 to under 12 years, the dose is 1/3 to 1/2 bottle, also accompanied by a full 8 oz glass of liquid. For children under 6 years of age, consultation with a healthcare professional is advised.

Clinicians should counsel patients to seek advice from a health professional if they are pregnant or breastfeeding before using the medication. No additional information is available regarding laboratory tests, abuse potential, or postmarketing experiences.

Drug Information (PDF)

This file contains official product information for Gadavyt, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)